Clinical Trial: A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma
Study Status: Completed
Recruit Status: RECRUITING
Condition: Cancer
Study Type: INTERVENTIONAL
Official Title: An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed/Refract
Brief Summary:
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of CRG-022, a CD22-directed autologous Chimeric Antigen Receptor (CAR) T-cell therapy for the treatment of relapsed or refractory large B-cell lymphoma (LBCL).
Read more